Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009

May 01 2009

Related Content

Deerfield To NitroMed: Not So Fast, Not So Cheap

Dec 04 2008

Merck Announces Major FOB Initiative With Its New Business Unit

Dec 09 2008

Novartis/MPM Option Fund Taps Fourth Prospect In Peptimmune

Jan 20 2009

Pharma’s Mega Mergers Reveal Divergent Strategies

Apr 20 2009

Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says

Jan 15 2009

Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme

Mar 23 2009

GSK’s Vallance Teams Up With Ex-University London Colleagues In Pentraxin Deal

Mar 25 2009

Novartis' New Kind of Pharma Deal

Apr 01 2008

Pfizer's Ambitions in the Off-Patent World

Mar 01 2009

Merck Buys Schering-Plough -- and Time

Mar 01 2009

Call the Plumber: PIPE Logic is Leaky

Apr 01 2009

Roche/Genentech: A Case Study For Future Hostile Offers

Feb 01 2009

A Two Pharma Horse Race In Follow-On Biologics

Feb 01 2009

Pfizer/Wyeth: Industrializing Pharma?

Feb 01 2009

GSK Tries to Mimic Real-World Biotech

Feb 01 2009

Roche's Acquisition of Genentech: Retention Program Unlikely to Stem Departures

Sep 01 2008

After Roche/Genentech: Pharma's Focus on Efficiencies, Not Innovation

Jul 01 2008

Pharma's Strategic Divide: Focus or Diversify

Sep 01 2008

Biotech Models: Bypassing VCs to Deal Direct with Pharma

Jan 01 2009

CVT And Gilead Look To Lock Out Astellas With Planned Merger

Mar 15 2009

Valuation Watch: Bargain Prices Not Enough to Flood PIPEs

Apr 01 2009

GSK/Pentraxin: Targeting SAP in Amyloidosis, and Maybe Alzheimer's Too

Apr 01 2009

Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash

Jan 14 2009

Merck's Head-long Leap into Follow-On Biologics

Dec 01 2008

Reacting to the Crisis: Biotech Venture Capital's Plan B

Dec 01 2008

Lilly Signs Cardiovascular Research Partnership With India’s Zydus Cadila

Mar 31 2009

Merck’s Ambitious Plans For Follow-On Biologics

Dec 15 2008

Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis

Feb 12 2009

A Goliath Grows: Pfizer To Buy Wyeth For $68 Billion

Feb 02 2009

Related Companies

U.S. Stem Cell, Inc.

Bristol Myers Squibb Company

Mead Johnson Nutrition Co.

ConvaTec Group PLC

Lantheus Holdings, Inc.

Oncolytics Biotech, Inc.

Vertex Pharmaceuticals Incorporated

SFJ Pharmaceuticals, Inc

Victory Pharma, Inc.

Proteon Therapeutics, Inc

Novartis AG

Anacor Pharmaceuticals, Inc.

GSK plc

Schering-Plough

Cadence Pharmaceuticals, Inc.

Pharmasset, Inc.

Wyeth

Pfizer Inc.

Merck & Co., Inc.

Aurobindo Pharma Limited

Additional Topics

BioPharmaceutical

More from Archive

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window